title: Schwartz et al. respond.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Schwartz
authors.forename: Jan
authors.initials: J
authors.lastname: Gryczynski
authors.forename: Kevin E
authors.initials: KE
authors.lastname: O'Grady
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Sharfstein
authors.forename: Gregory
authors.initials: G
authors.lastname: Warren
authors.forename: Yngvild K
authors.initials: YK
authors.lastname: Olsen
authors.forename: Shannon Gwin
authors.initials: SG
authors.lastname: Mitchell
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Jaffe
mesh_terms: D002047:Buprenorphine / Q000627:therapeutic use*; D062787:Drug Overdose / Q000401:mortality*; D006556:Heroin Dependence / Q000401:mortality*; D006801:Humans; D008691:Methadone / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment / Q000639:trends*
chemical_list: D002047:Buprenorphine; D008691:Methadone